Parkinson's Community Plays Important Role in Supporting NIH Focus on Translational Research
Michael J. Fox Foundation CEO, Dr. Todd Sherer, testified before the U.S. House Subcommittee on Labor, Health and Human Services, Education, and Related Agencies today in support of the National Center for the Advancement of Translational Sciences (NCATS) at the National Institutes of Health (NIH). NIH Director Francis Collins opened the hearing with an overview of NCATS' mission to re-engineer the therapy development pipeline. Acting NCATS Director Thomas Insel also spoke about the need for NIH to focus on translational research in a more efficient and effective manner. Following questions from the members of the Subcommittee, a second panel – Sherer, Dr. Scott Koenig (president and CEO of Macrogenics), and Dr. Roy Vagelos (Chairman of Regeneron Pharmaceuticals) – shared their viewpoints on the role NIH can play in translational research.
Parkinson's Action Network CEO Amy Comstock Rick attended the hearing and said, "To have the Parkinson's community represented in these discussions is important not just for people with Parkinson's, but also for the entire biomedical research field. Good research informs other research, and can get us closer to better treatments and, ultimately, a cure. Having a seat at the table for important business such as this is one more way we are the unified voice of the Parkinson's community."
To read more about Sherer's testimony , and the hearing, visit the Michael J. Fox Foundation for Parkinson's Research Blog. 
To read more about the creation of NCATS and what it means for the future of therapy development, click here.